Terms ending in 2043
Every in-force patent on AbbVie Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,964,990 | 1,3,4,7-Tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[2,3-b][1,4]oxazepine Bcl-2 Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 12,655,210 | Anti-Hemojuvelin (HJV) Antibodies for Treating Anemia of Chronic Disease In force · High confidence | AbbVie Deutschland GmbH & Co. KG | In force | High confidence | |
| US 12,172,992 | Pyrimidines for Degrading Bruton's Tyrosine Kinase In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 11,993,613 | Thiazolo[5,4-b]pyridine MALT-1 Inhibitors In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 12,121,589 | ANTI-CD19 Antibody Drug Conjugates In force · High confidence | AbbVie Biotherapeutics Inc. | In force | High confidence | |
| US 12,478,689 | ANTI-CD19 Antibody Drug Conjugates In force · Medium confidence | AbbVie Biotherapeutics Inc. | In force | Medium confidence | |
| US 12,799,192 | Risankizumab Compositions In force · High confidence | AbbVie Inc. | In force | High confidence | |
| US 12,157,776 | Anti-Papp-A Antibodies and Methods of Use Thereof In force · High confidence | Calico Life Sciences LLC | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
7 of these are in force and held by AbbVie Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.